Spots Global Cancer Trial Database for pharmacological study

Every month we try and update this database with for pharmacological study cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT01375829	Adult Solid Neo...	Ixabepilone Pharmacological... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	NCT00390000	Unspecified Adu...	vatalanib pemetrexed diso... pharmacological... ultrasound imag...	18 Years -	Mayo Clinic
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	NCT02522715	Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone	18 Years -	OHSU Knight Cancer Institute
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment	NCT00822458	Recurrent Child...	vismodegib laboratory biom... pharmacological...	3 Years - 21 Years	National Cancer Institute (NCI)
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy	NCT01147029	Unspecified Adu...	angiogenesis in... laboratory biom... pharmacological... dynamic contras...	18 Years -	Cancer Research UK
Sunitinib Malate in Treating Patients With Kidney Cancer	NCT00943839	Kidney Cancer	sunitinib malat... laboratory biom... pharmacological...	18 Years -	Centre Antoine Lacassagne
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)	NCT00365209	Healthy, no Evi... Tobacco Use Dis...	laboratory biom... pharmacological... curcumin	40 Years -	National Cancer Institute (NCI)
Pharmacokinetics of Dactinomycin in Young Patients With Cancer	NCT00900354	Unspecified Chi...	molecular genet... mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	NCT02453620	Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid...	Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer	NCT01120236	Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological...	18 Years -	National Cancer Institute (NCI)
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors	NCT00471432	Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu...	custirsen sodiu... docetaxel pharmacological...	18 Years - 120 Years	Canadian Cancer Trials Group
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma	NCT01476839	Recurrent Adult...	basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la...	18 Years - 70 Years	City of Hope Medical Center
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	NCT01823198	Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related...	Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological...	7 Years - 65 Years	M.D. Anderson Cancer Center
Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer	NCT00547612	Pancreatic Canc...	high performanc... pharmacological... [18F]-labeled s...	18 Years -	National Institutes of Health Clinical Center (CC)
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas	NCT00042991	Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child...	gefitinib radiation thera... pharmacological... laboratory biom...	3 Years - 21 Years	National Cancer Institute (NCI)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma	NCT01979523	Recurrent Uveal... Stage IV Uveal ...	Laboratory Biom... Pharmacological... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis	NCT03252600	Recurrent Prima...	Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma	NCT02363283	Recurrent Uveal... Stage IV Uveal ...	Glembatumumab V... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
SU6668 in Treating Patients With Advanced Solid Tumors	NCT00024206	Unspecified Adu...	orantinib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery	NCT01537107	Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu...	vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose...	18 Years -	Mayo Clinic
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	NCT00423735	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult...	Dasatinib Pharmacological...	18 Years -	National Cancer Institute (NCI)
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	NCT00770471	Brain and Centr...	temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera...	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02299518	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer	NCT00118040	Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd...	Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma	NCT00514085	Melanoma (Skin)	recombinant hum... immunohistochem... laboratory biom... pharmacological...	18 Years -	Canadian Cancer Trials Group
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	NCT01918306	Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative...	cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941	18 Years -	Vanderbilt-Ingram Cancer Center
Diindolylmethane in Preventing Cancer in Healthy Volunteers	NCT00784394	Healthy, no Evi...	diindolylmethan... placebo pharmacological... laboratory biom... quality-of-life...	18 Years - 70 Years	National Cancer Institute (NCI)
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer	NCT02178436	Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre...	gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel	19 Years -	Barbara Ann Karmanos Cancer Institute
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT03333746	Recurrent Plasm... Refractory Plas...	Laboratory Biom... Lenalidomide Nivolumab Pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	NCT02996825	Recurrent Breas... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Triple-Negative...	Gemcitabine Gemcitabine Hyd... Laboratory Biom... Mirvetuximab So... Pharmacological...	-	City of Hope Medical Center
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors	NCT00547131	Brain and Centr... Metastatic Canc...	temozolomide laboratory biom... liquid chromato... mass spectromet... pharmacological... conventional su... stereotactic ra...	18 Years - 120 Years	City of Hope Medical Center
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT00110019	Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors	NCT01154426	Adult Solid Neo... BRCA1 Mutation ... BRCA2 Mutation ...	Diagnostic Labo... Gemcitabine Hyd... Pharmacological... Veliparib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma	NCT03126630	Pleural Maligna...	Anetumab Ravtan... Laboratory Biom... Pembrolizumab Pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	NCT00550784	Fallopian Tube ... Ovarian Cancer Peritoneal Cavi...	filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo...	- 60 Years	City of Hope Medical Center
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma	NCT00521092	AIDS-related Ka... Classic Kaposi ...	sunitinib malat... laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	NCT00538187	Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small...	obatoclax mesyl... bortezomib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors	NCT02324621	Unspecified Adu...	Oral ONC201 pharmacological... laboratory biom...	18 Years -	Rutgers, The State University of New Jersey
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery	NCT01061411	Clear Cell Sarc... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Dalteparin Pharmacological... Sunitinib Malat...	18 Years -	Roswell Park Cancer Institute
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	NCT01074411	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate...	Bortezomib Carboplatin Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer	NCT02048943	Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unspecified Adu...	dovitinib lacta... gemcitabine hyd... paclitaxel albu... pharmacological... laboratory biom...	18 Years -	Roswell Park Cancer Institute
MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery	NCT01098344	Pancreatic Canc...	Notch signaling... gemcitabine hyd... imaging biomark... laboratory biom... pharmacological...	18 Years -	Cancer Research UK
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer	NCT02184533	Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma	sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a...	18 Years -	Stanford University
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung	NCT01013831	Dysplasia Metaplasia Pulmonary Preca...	Erlotinib Hydro... Laboratory Biom... Pharmacological...	40 Years - 79 Years	National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	NCT03526250	Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Laboratory Biom... Palbociclib Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	NCT01048892	Adrenocortical ... Gastrointestina... Kidney Cancer Neuroblastoma Retinoblastoma Sarcoma	Seneca Valley v... cyclophosphamid... laboratory biom... pharmacological...	3 Years - 21 Years	Children's Oncology Group
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer	NCT01876446	Recurrent Small...	Laboratory Biom... Pegylated Irino... Pharmacological...	18 Years -	Roswell Park Cancer Institute
Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy	NCT00559481	Prostate Cancer	dexamethasone ketoconazole therapeutic hyd... pharmacological...	-	Roswell Park Cancer Institute
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy	NCT01208064	Lung Cancer	pazopanib hydro... laboratory biom... pharmacogenomic... pharmacological... quality-of-life...	18 Years - 120 Years	European Organisation for Research and Treatment of Cancer - EORTC
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors	NCT00039390	Unspecified Adu...	capecitabine gefitinib pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia	NCT00039117	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Secondary Acute... Untreated Adult...	oblimersen sodi... cytarabine daunorubicin hy... laboratory biom... pharmacological...	60 Years -	National Cancer Institute (NCI)
Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer	NCT02227940	Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre...	Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological...	18 Years -	Roswell Park Cancer Institute
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Kidney Cancer	NCT00943839	Kidney Cancer	sunitinib malat... laboratory biom... pharmacological...	18 Years -	Centre Antoine Lacassagne
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	NCT00052780	Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child...	O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom...	- 21 Years	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors	NCT00513981	Brain and Centr... Sarcoma Unspecified Chi...	leucovorin calc... methotrexate mass spectromet... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT01989598	Recurrent Plasm... Refractory Plas...	Laboratory Biom... Pharmacological... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia	NCT03009240	Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult...	Decitabine Laboratory Biom... Pevonedistat Pharmacological...	18 Years -	City of Hope Medical Center
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery	NCT00667901	Melanoma (Skin)	riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con...	18 Years -	Rutgers, The State University of New Jersey
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer	NCT01582191	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Everolimus Laboratory Biom... Pharmacological... Vandetanib	-	M.D. Anderson Cancer Center
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant	NCT03015792	Recurrent Plasm... Refractory Plas...	Dexamethasone Ibrutinib Laboratory Biom... Lenalidomide Pharmacological... Quality-of-Life...	18 Years -	Mayo Clinic
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas	NCT03220022	AIDS-Related Ly... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage...	Cyclophosphamid... Doxorubicin Hyd... Etoposide Filgrastim Ibrutinib Laboratory Biom... Pegfilgrastim Pharmacological... Prednisone Rituximab Vincristine Sul...	18 Years -	National Cancer Institute (NCI)
Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma	NCT00003909	Untreated Child...	motexafin gadol... radiation thera... pharmacological...	- 21 Years	National Cancer Institute (NCI)
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia	NCT01627041	Acute Myeloid L... Adult Acute Bas... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Alkylating Agen... Secondary Acute...	Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological...	18 Years - 65 Years	National Cancer Institute (NCI)
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy	NCT01294306	Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Squamous Cell L...	Akt Inhibitor M... Erlotinib Hydro... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis	NCT00030381	Primary Systemi...	4'-iodo-4'-deox... pharmacological...	18 Years -	National Cancer Institute (NCI)
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	NCT02101853	Recurrent B Acu...	Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul...	1 Year - 31 Years	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission	NCT00522301	Fallopian Tube ... Ovarian Cancer Primary Periton...	sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma	NCT00387751	Recurrent Melan... Stage III Skin ... Stage IV Skin M...	Bevacizumab Laboratory Biom... Pharmacological... Sorafenib Tosyl...	18 Years - 120 Years	National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors	NCT00072436	Unspecified Adu...	gemcitabine hyd... alvocidib pharmacological...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: